WO2025092695 - NEW HETEROCYCLIC COVALENT INHIBITOR OF MENIN, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/092695
Publication Date
08.05.2025
International Application No.
PCT/CN2024/127957
International Filing Date
29.10.2024
Title **
[English]
NEW HETEROCYCLIC COVALENT INHIBITOR OF MENIN, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF
[French]
NOUVEL INHIBITEUR COVALENT HÉTÉROCYCLIQUE DE LA MÉNINE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION PHARMACEUTIQUE
[Chinese]
一种新型杂环类menin共价作用抑制剂、其制备方法及医药用途
Applicants **
CHENGDU EASTON BIOPHARMACEUTICALS CO., LTD.
Inventors
HE, Yun
XIONG, Qian
SU, Huasheng
ZHAO, Dezhi
MA, Zhen
LI, Li
QIAO, Zhitao
WANG, Ying
Priority Data
202311422322.0
31.10.2023
CN
202410426375.8
10.04.2024
CN
202411182228.7
27.08.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1821 | |
| EPO | Filing, Examination, Granting | 12078 | |
| Japan | Filing, Examination, Granting | 1952 | |
| South Korea | Filing, Examination, Granting | 1729 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,320
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided in the present invention are a compound of formula (I), a pharmaceutically acceptable salt thereof, a preparation method therefor and the use thereof. The compound can be used as a medicament in the treatment of diseases and disorders, including cancers and other diseases mediated by menin-MLL interactions.[French]
La présente invention concerne un composé de formule (I), un sel pharmaceutiquement acceptable de celui-ci, un procédé de préparation s'y rapportant et une utilisation médicale associée. Le composé peut être utilisé en tant que médicament dans le traitement de maladies et de troubles, y compris des cancers et d'autres maladies médiées par des interactions ménine-MLL.[Chinese]
本发明提供式(I)化合物、其药用盐及其制备方法和用途。该化合物在治疗疾病和病症中可用作药剂，所述疾病和病症包括癌症，由menin-MLL相互作用介导的其它疾病。